In all fairness tackling Renal and Heart Failure with further...

In all fairness tackling Renal and Heart Failure with further trials and private payor coverage is going to require significant capital. We are no longer talking a one trick pony here. While the lymphoedema trial is under the belt further avenues are yet to come. We could literally be talking multiple devices in each major hospital if a SOZO is recognised to be the gold standard for measuring fluid for all 3 ailments. The revenue streams down the track could be extremely profitable and ongoing on a $ per test basis once the wheels are in motion. As usual in this sector significant outlays required to get there first.